C
Chang Won Kim
Researcher at Pusan National University
Publications - 2
Citations - 786
Chang Won Kim is an academic researcher from Pusan National University. The author has contributed to research in topics: Hepatocellular carcinoma & Oncolytic virus. The author has an hindex of 2, co-authored 2 publications receiving 693 citations.
Papers
More filters
Journal ArticleDOI
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo,Tony R. Reid,Leyo Ruo,Caroline J. Breitbach,Steven C. Rose,Mark Bloomston,Mong Cho,Ho Yeong Lim,Hyun Cheol Chung,Chang Won Kim,James M. Burke,Riccardo Lencioni,Theresa Hickman,Anne Moon,Yeon Sook Lee,Mi Kyeong Kim,Manijeh Daneshmand,Kara S DuBois,Lara Longpre,Minhtran C. Ngo,Cliona M. Rooney,John C. Bell,Byung Geon Rhee,Richard H. Patt,Tae-Ho Hwang,David H. Kirn +25 more
TL;DR: JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC, and subject survival duration was significantly related to dose.
Journal ArticleDOI
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo,Caroline J. Breitbach,Anne Moon,Chang Won Kim,Rick Patt,Mi-Kyung Kim,Yu Kyung Lee,Sung Yong Oh,Hyun Young Woo,Kelley Parato,Julia L Rintoul,Theresa Falls,Theresa Hickman,Byung-Geon Rhee,John C. Bell,David H. Kirn,Tae-Ho Hwang +16 more
TL;DR: Treatment of HCC with JX-594 followed by sorafenib has antitumoral activity, and Jx-594 may sensitize tumors to subsequent therapy with VEGF/VEGFR inhibitors.